RICHMOND, Calif. (AP) _ Sangamo Therapeutics Inc. (SGMO) on Thursday reported a loss of $12.4 million in its third quarter.
The Richmond, California-based company said it had a loss of 15 cents per share.
The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 20 cents per share.
The drug developer posted revenue of $11.8 million in the period, also surpassing Street forecasts. Three analysts surveyed by Zacks expected $9.4 million.
Sangamo expects full-year revenue in the range of $30 million to $40 million.
Sangamo shares have more than quadrupled since the beginning of the year. In the final minutes of trading on Thursday, shares hit $12.30, more than tripling in the last 12 months.